Luminari CRO adds Ramzi Dagher as strategic advisor

Luminari CRO has named physician and drug development leader Ramzi Dagher, MD, as a strategic advisor as the Miami company expands its AI-driven approach to pharmaceutical development. Dagher will make his first public appearance for the company at Paperless Lab Academy® USA in Cambridge, Massachusetts, Oct. 12-14, 2026.

Why it matters: - Luminari CRO is trying to pair artificial intelligence with clinical, scientific and regulatory expertise as drug development becomes more data-driven. - Dagher's background in oncology, regulatory science and pharmaceutical research gives the company added credibility as it pushes AI-enabled drug development workflows.

What happened: - Luminari CRO announced Oct. 8, 2026, that Ramzi Dagher, MD, has joined the company as a strategic advisor. - Dagher brings experience from the U.S. Food and Drug Administration, the National Cancer Institute and pharmaceutical-industry leadership roles. - Dagher will make his first public appearance representing Luminari CRO at the Paperless Lab Academy® USA Conference Oct. 12-14, 2026, in Cambridge, Massachusetts. - Luminari CRO is sponsoring the conference, and Dagher will attend the event to discuss AI, pharmaceutical development, scientific data and clinical decision-making.

The details: - Dagher's background spans oncology, clinical research, regulatory strategy and evaluation of emerging therapies. - Luminari CRO said Dagher's experience will help inform the company's AI-enabled approaches to complex drug-development challenges. - CEO Yuri Zamostin said AI in pharmaceutical development must be grounded in real-world scientific and clinical expertise. - Dagher said the opportunity is to combine AI with existing scientific, clinical and regulatory knowledge to improve analysis, decision-making and development efficiency. - Zamostin said scientific informatics is evolving from information management to connecting data, science, people and decisions. - Dagher has contributed to the development and evaluation of therapies in oncology, infectious diseases and other disease areas. - Dagher has also published on drug development and regulatory topics. - Luminari CRO says it combines pharmaceutical development expertise, technology and artificial intelligence to improve development processes, decision-making and operational efficiency while maintaining scientific and regulatory rigor.

Between the lines: - The hire signals that Luminari CRO wants to differentiate its AI strategy with domain expertise, not just software tools. - The conference appearance gives the company a public stage to position itself inside the growing market for AI in life sciences.

What's next: - Dagher's first visible role for Luminari CRO will be at Paperless Lab Academy® USA. - Luminari CRO is likely to keep presenting its AI approach as a blend of technology, scientific knowledge and regulatory discipline.

The bottom line: - Luminari CRO is betting that AI in drug development will gain traction faster when paired with seasoned medical and regulatory leadership.